Table 3. Severity and clinical management of asthma population prescribed 1–9 ICS+COMBI per year, by number of SABA inhalers (N=20,884).
| Total N (%) | 1–3 N (%) | 4–12 N (%) | 13+N (%) | |
|---|---|---|---|---|
| 20,884 | 9,451 (45.3) | 10,285 (49.3) | 1,148 (5.5) | |
|
Clinical measures | ||||
| Asthma review | 19,787 (94.8) | 8,739 (92.5) | 9,919 (96.4) | 1,129 (98.3) |
| Asthma management plan | 17,471 (83.7) | 7,603 (80.5) | 8,848 (86.0) | 1,020 (88.9) |
| Asthma step recorded | 18,498 (88.6) | 7,986 (84.5) | 9,435 (91.7) | 1,077 (93.8) |
|
Asthma severitya | ||||
| Step 1 | 3,060 (16.5) | 1,621 (20.3) | 1,313 (13.9) | 126 (11.7) |
| Step 2 | 11,929 (64.5) | 5,279 (66.1) | 6,085 (64.5) | 565 (52.5) |
| Step 3 | 3,153 (17.1) | 1,023 (12.8) | 1,831 (19.4) | 299 (27.8) |
| Step 4/5 | 356 (1.9) | 63 (0.8) | 206 (2.2) | 87 (8.1) |
|
Healthcare resource use | ||||
| Count IP episodes | 447 | 122 | 239 | 86 |
| Crude IP episode, rate per 100 population | 2.14 | 1.29 | 2.32 | 7.49 |
Abbreviations: COMBI, combination inhalers (ICS and Long-acting β2-agonist); ICS, inhaled corticosteroid; IP, inpatient; SABA, short-acting β2-agonist.
a
Asthma step % as a proportion of total with asthma step recorded.